, NSG 533 Advanced Pharmacology Practice Exam with
Questions and Correct Answers/ Advanced Pharmacology NSG
533 Practice Test Latest - 145 Questions
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-15)
1 A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (CL) of 50 L/hr. Which of the following
best describes the expected half-life (t½) and the clinical implication of such a large Vd?
A) t½ = 5 hours; the drug is primarily confined to the vascular compartment.
B) t½ = 10 hours; the drug is likely highly protein-bound and restricted to plasma.
C) t½ = 7 hours; a loading dose may be required to achieve therapeutic concentrations rapidly.
D) t½ = 6.93 hours; the drug is extensively distributed into tissues, possibly sequestered in fat or bone.
Answer: D
Rationale: Half-life is calculated as t½ = 0.693 * Vd / CL = 0.693 * = 6.93 hours. A Vd of 500 L (far
exceeding total body water ~42 L) indicates extensive tissue distribution, often due to lipophilicity or binding to
tissue proteins. This necessitates a loading dose to rapidly saturate tissue compartments and achieve effective
plasma concentrations. Option A describes a drug confined to plasma (Vd ~3-5 L). Option B's t½ is incorrect and
high protein binding typically restricts Vd. Option C's t½ is incorrect.
2 A drug follows Michaelis-Menten elimination kinetics with a Vmax of 500 mg/day and Km of 10 mg/L. If the
patient has a steady-state concentration (Css) of 20 mg/L on a daily dose of 400 mg, what is the approximate
clearance at this concentration?
A) 12.5 L/day
B) 16.7 L/day
C) 25 L/day
D) 33.3 L/day
Answer: B
Rationale: For Michaelis-Menten kinetics, clearance is concentration-dependent: CL = Vmax / (Km + C). At Css =
20 mg/L, CL = 500 / (10 + 20) = 500/30 = 16.67 L/day. Option A (12.5 L/day) would correspond to a higher Css
(30 mg/L). Option C (25 L/day) would be CL at Css = 10 mg/L (Km). Option D (33.3 L/day) would occur at Css =
5 mg/L. Understanding this nonlinearity is critical for drugs like phenytoin.
3 A novel analgesic binds to -opioid receptors with a dissociation constant (Kd) of 0.5 nM and produces a
maximal response (Emax) equal to that of morphine. In a receptor binding assay, the drug displaces 50% of a
radioligand at 2 nM. Which of the following best characterizes this drug?
A) Full agonist with lower affinity than morphine; Kd = 2 nM.
B) Partial agonist with Kd = 0.5 nM; the discrepancy suggests negative cooperativity.
C) Full agonist; the IC50 of 2 nM indicates lower potency, but affinity cannot be directly inferred without
knowing the radioligand Kd.
D) Inverse agonist; the IC50 of 2 nM is consistent with constitutive receptor activity.
Answer: C
Rationale: The drug is a full agonist (Emax = morphine). The Kd (0.5 nM) is a measure of affinity, while the IC50
(2 nM) is the concentration displacing 50% of radioligand; IC50 depends on radioligand concentration and its own
Kd. Without the Cheng-Prusoff correction, IC50 Kd. Option A incorrectly equates IC50 to Kd. Option B is wrong
because partial agonists have lower Emax. Option D is incorrect; inverse agonists reduce constitutive activity, not
,relevant here.
4 A drug is a weak base with pKa = 8.0. It is administered intravenously and undergoes renal excretion. If the
urine pH is 5.0, what is the approximate ratio of ionized to unionized drug in the urine, and how does this affect
reabsorption?
A) Ratio 1000:1; reabsorption is minimal due to ion trapping.
B) Ratio 1000:1; reabsorption is enhanced because the unionized form is abundant.
C) Ratio 0.001:1; reabsorption is minimal due to low unionized concentration.
D) Ratio 0.001:1; reabsorption is enhanced because the ionized form is trapped.
Answer: A
Rationale: Using the Henderson-Hasselbalch equation for bases: pH = pKa + log([B]/[BH+]). Rearranged:
log([B]/[BH+]) = pH - pKa = 5 - 8 = -3, so [B]/[BH+] = 10^-3 = 0.001. Thus, [BH+]/[B] = 1000:1
(ionized:unionized). In acidic urine, a weak base is predominantly ionized, reducing reabsorption (ion trapping).
Option B incorrectly states reabsorption is enhanced. Options C and D reverse the ratio.
5 A drug is 99% bound to plasma albumin and has a hepatic extraction ratio of 0.05. Which of the following
statements best predicts the effect of a drug-drug interaction that displaces 10% of the bound drug?
A) Clearance will increase by approximately 10-fold because free fraction increases from 0.01 to 0.11.
B) Clearance will increase minimally because the drug's clearance is limited by intrinsic clearance (low
extraction).
C) Clearance will decrease due to increased volume of distribution from displacement.
D) Clearance will remain unchanged because protein binding does not affect low extraction drugs.
Answer: B
Rationale: For a low extraction ratio drug (E=0.05), clearance is approximated by CL = fu * CLint, where fu is free
fraction. Initially fu=0.01; after displacement fu=0.11 (10% of 99% bound is displaced, so bound becomes 89%,
free 11%). However, the increase in fu is 11-fold, but the change in unbound concentration at the enzyme site also
depends on blood flow and intrinsic clearance. For low E drugs, CL is sensitive to fu, but the increase in CL is not
10-fold because the extraction ratio remains low; the increase is proportional but often less dramatic due to
compensatory changes. More importantly, the clinical impact is on free concentration, not total clearance. Option A
overestimates the change. Option C is incorrect: displacement increases Vd but doesn't decrease CL. Option D is
false: low extraction drugs are sensitive to binding changes.
6 A drug follows a two-compartment model with rapid distribution ( half-life = 0.5 hr) and slow elimination (
half-life = 12 hr). After a single IV bolus dose, when is the drug's concentration most likely to be in the
post-distributive () phase?
A) Immediately after injection during the first 30 minutes.
B) Between 1 and 2 hours after injection.
C) After approximately 3-4 hours, once distribution is complete.
D) Only after 5 half-lives of the phase (60 hours).
Answer: C
Rationale: I n a t w o - c o m p a r t m e n t m o d e l , t h e ± p h a s
2-2.5 hours (5 * 0.5 = 2.5 hr). After that, the drug is in the (elimination) phase. Option A is the phase. Option B is
still predominantly distribution. Option D is incorrect; the phase begins much earlier.
7 A drug has a therapeutic index (TI) of 2. Which of the following dosing strategies is most appropriate to
maximize efficacy while minimizing toxicity, given that the drug exhibits linear pharmacokinetics?
A) Administer a loading dose followed by maintenance doses adjusted based on trough concentrations.
, B) Use a fixed dose at the maximum tolerated dose to ensure efficacy.
C) Administer the drug as a continuous infusion to maintain steady-state within the therapeutic window.
D) Use intermittent bolus dosing with extended intervals to allow complete washout.
Answer: C
Rationale: A narrow TI (2) means the toxic concentration is only twice the minimum effective concentration.
Continuous infusion provides the best control to maintain concentrations within this narrow window, avoiding
peaks that cause toxicity and troughs that are subtherapeutic. Option A (loading dose) could cause toxicity. Option
B (maximum tolerated dose) risks toxicity. Option D (extended intervals) may lead to subtherapeutic periods.
8 A drug is a substrate of CYP3A4 and P-glycoprotein (P-gp). When co-administered with a potent CYP3A4
inhibitor, which of the following is most likely to occur?
A) Increased oral bioavailability due to reduced first-pass metabolism, and increased brain penetration due to
P-gp inhibition.
B) Decreased oral bioavailability due to increased efflux by P-gp, and unchanged brain penetration.
C) Increased oral bioavailability but decreased brain penetration due to P-gp induction.
D) No change in oral bioavailability because P-gp compensates for CYP3A4 inhibition.
Answer: A
Rationale: CYP3A4 inhibition reduces gut wall and hepatic metabolism, increasing oral bioavailability. Many
CYP3A4 inhibitors also inhibit P-gp (e.g., verapamil, ketoconazole), reducing efflux at the blood-brain barrier and
increasing brain penetration. Option B is opposite. Option C: P-gp induction is not typical with CYP3A4 inhibitors.
Option D: P-gp and CYP3A4 often work synergistically; inhibition of one does not fully compensate.
9 A drug is eliminated solely by glomerular filtration (no secretion or reabsorption). The patient has a glomerular
filtration rate (GFR) of 30 mL/min. If the normal GFR is 120 mL/min and the drug's normal half-life is 4 hours,
what is the expected half-life in this patient?
A) 1 hour
B) 4 hours
C) 12 hours
D) 16 hours
Answer: D
Rationale: For a drug eliminated solely by filtration, clearance is proportional to GFR. Half-life is inversely
proportional to clearance: t½ 1/CL. If GFR is reduced to 30/120 = 1/4 of normal, clearance is 1/4, so half-life
increases 4-fold: 4 * 4 = 16 hours. Option A (1 hr) would be increased clearance. Option B (4 hr) assumes no
change. Option C (12 hr) is 3-fold, not 4-fold.
10 A drug has an elimination rate constant (k) of 0.2 hr¹ and a volume of distribution (Vd) of 50 L. If a continuous
IV infusion is started at a rate of 100 mg/hr, what is the predicted steady-state concentration (Css)?
A) 5 mg/L
B) 10 mg/L
C) 20 mg/L
D) 40 mg/L
Answer: B
Rationale: C l e a r a n c e ( C L ) = k * V d = 0 . 2 h r{ ¹ * 5 0
mg/L. Option A (5 mg/L) would require CL=20 L/hr. Option C (20 mg/L) would require CL=5 L/hr. Option D (40
mg/L) would require CL=2.5 L/hr.
Questions and Correct Answers/ Advanced Pharmacology NSG
533 Practice Test Latest - 145 Questions
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-15)
1 A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (CL) of 50 L/hr. Which of the following
best describes the expected half-life (t½) and the clinical implication of such a large Vd?
A) t½ = 5 hours; the drug is primarily confined to the vascular compartment.
B) t½ = 10 hours; the drug is likely highly protein-bound and restricted to plasma.
C) t½ = 7 hours; a loading dose may be required to achieve therapeutic concentrations rapidly.
D) t½ = 6.93 hours; the drug is extensively distributed into tissues, possibly sequestered in fat or bone.
Answer: D
Rationale: Half-life is calculated as t½ = 0.693 * Vd / CL = 0.693 * = 6.93 hours. A Vd of 500 L (far
exceeding total body water ~42 L) indicates extensive tissue distribution, often due to lipophilicity or binding to
tissue proteins. This necessitates a loading dose to rapidly saturate tissue compartments and achieve effective
plasma concentrations. Option A describes a drug confined to plasma (Vd ~3-5 L). Option B's t½ is incorrect and
high protein binding typically restricts Vd. Option C's t½ is incorrect.
2 A drug follows Michaelis-Menten elimination kinetics with a Vmax of 500 mg/day and Km of 10 mg/L. If the
patient has a steady-state concentration (Css) of 20 mg/L on a daily dose of 400 mg, what is the approximate
clearance at this concentration?
A) 12.5 L/day
B) 16.7 L/day
C) 25 L/day
D) 33.3 L/day
Answer: B
Rationale: For Michaelis-Menten kinetics, clearance is concentration-dependent: CL = Vmax / (Km + C). At Css =
20 mg/L, CL = 500 / (10 + 20) = 500/30 = 16.67 L/day. Option A (12.5 L/day) would correspond to a higher Css
(30 mg/L). Option C (25 L/day) would be CL at Css = 10 mg/L (Km). Option D (33.3 L/day) would occur at Css =
5 mg/L. Understanding this nonlinearity is critical for drugs like phenytoin.
3 A novel analgesic binds to -opioid receptors with a dissociation constant (Kd) of 0.5 nM and produces a
maximal response (Emax) equal to that of morphine. In a receptor binding assay, the drug displaces 50% of a
radioligand at 2 nM. Which of the following best characterizes this drug?
A) Full agonist with lower affinity than morphine; Kd = 2 nM.
B) Partial agonist with Kd = 0.5 nM; the discrepancy suggests negative cooperativity.
C) Full agonist; the IC50 of 2 nM indicates lower potency, but affinity cannot be directly inferred without
knowing the radioligand Kd.
D) Inverse agonist; the IC50 of 2 nM is consistent with constitutive receptor activity.
Answer: C
Rationale: The drug is a full agonist (Emax = morphine). The Kd (0.5 nM) is a measure of affinity, while the IC50
(2 nM) is the concentration displacing 50% of radioligand; IC50 depends on radioligand concentration and its own
Kd. Without the Cheng-Prusoff correction, IC50 Kd. Option A incorrectly equates IC50 to Kd. Option B is wrong
because partial agonists have lower Emax. Option D is incorrect; inverse agonists reduce constitutive activity, not
,relevant here.
4 A drug is a weak base with pKa = 8.0. It is administered intravenously and undergoes renal excretion. If the
urine pH is 5.0, what is the approximate ratio of ionized to unionized drug in the urine, and how does this affect
reabsorption?
A) Ratio 1000:1; reabsorption is minimal due to ion trapping.
B) Ratio 1000:1; reabsorption is enhanced because the unionized form is abundant.
C) Ratio 0.001:1; reabsorption is minimal due to low unionized concentration.
D) Ratio 0.001:1; reabsorption is enhanced because the ionized form is trapped.
Answer: A
Rationale: Using the Henderson-Hasselbalch equation for bases: pH = pKa + log([B]/[BH+]). Rearranged:
log([B]/[BH+]) = pH - pKa = 5 - 8 = -3, so [B]/[BH+] = 10^-3 = 0.001. Thus, [BH+]/[B] = 1000:1
(ionized:unionized). In acidic urine, a weak base is predominantly ionized, reducing reabsorption (ion trapping).
Option B incorrectly states reabsorption is enhanced. Options C and D reverse the ratio.
5 A drug is 99% bound to plasma albumin and has a hepatic extraction ratio of 0.05. Which of the following
statements best predicts the effect of a drug-drug interaction that displaces 10% of the bound drug?
A) Clearance will increase by approximately 10-fold because free fraction increases from 0.01 to 0.11.
B) Clearance will increase minimally because the drug's clearance is limited by intrinsic clearance (low
extraction).
C) Clearance will decrease due to increased volume of distribution from displacement.
D) Clearance will remain unchanged because protein binding does not affect low extraction drugs.
Answer: B
Rationale: For a low extraction ratio drug (E=0.05), clearance is approximated by CL = fu * CLint, where fu is free
fraction. Initially fu=0.01; after displacement fu=0.11 (10% of 99% bound is displaced, so bound becomes 89%,
free 11%). However, the increase in fu is 11-fold, but the change in unbound concentration at the enzyme site also
depends on blood flow and intrinsic clearance. For low E drugs, CL is sensitive to fu, but the increase in CL is not
10-fold because the extraction ratio remains low; the increase is proportional but often less dramatic due to
compensatory changes. More importantly, the clinical impact is on free concentration, not total clearance. Option A
overestimates the change. Option C is incorrect: displacement increases Vd but doesn't decrease CL. Option D is
false: low extraction drugs are sensitive to binding changes.
6 A drug follows a two-compartment model with rapid distribution ( half-life = 0.5 hr) and slow elimination (
half-life = 12 hr). After a single IV bolus dose, when is the drug's concentration most likely to be in the
post-distributive () phase?
A) Immediately after injection during the first 30 minutes.
B) Between 1 and 2 hours after injection.
C) After approximately 3-4 hours, once distribution is complete.
D) Only after 5 half-lives of the phase (60 hours).
Answer: C
Rationale: I n a t w o - c o m p a r t m e n t m o d e l , t h e ± p h a s
2-2.5 hours (5 * 0.5 = 2.5 hr). After that, the drug is in the (elimination) phase. Option A is the phase. Option B is
still predominantly distribution. Option D is incorrect; the phase begins much earlier.
7 A drug has a therapeutic index (TI) of 2. Which of the following dosing strategies is most appropriate to
maximize efficacy while minimizing toxicity, given that the drug exhibits linear pharmacokinetics?
A) Administer a loading dose followed by maintenance doses adjusted based on trough concentrations.
, B) Use a fixed dose at the maximum tolerated dose to ensure efficacy.
C) Administer the drug as a continuous infusion to maintain steady-state within the therapeutic window.
D) Use intermittent bolus dosing with extended intervals to allow complete washout.
Answer: C
Rationale: A narrow TI (2) means the toxic concentration is only twice the minimum effective concentration.
Continuous infusion provides the best control to maintain concentrations within this narrow window, avoiding
peaks that cause toxicity and troughs that are subtherapeutic. Option A (loading dose) could cause toxicity. Option
B (maximum tolerated dose) risks toxicity. Option D (extended intervals) may lead to subtherapeutic periods.
8 A drug is a substrate of CYP3A4 and P-glycoprotein (P-gp). When co-administered with a potent CYP3A4
inhibitor, which of the following is most likely to occur?
A) Increased oral bioavailability due to reduced first-pass metabolism, and increased brain penetration due to
P-gp inhibition.
B) Decreased oral bioavailability due to increased efflux by P-gp, and unchanged brain penetration.
C) Increased oral bioavailability but decreased brain penetration due to P-gp induction.
D) No change in oral bioavailability because P-gp compensates for CYP3A4 inhibition.
Answer: A
Rationale: CYP3A4 inhibition reduces gut wall and hepatic metabolism, increasing oral bioavailability. Many
CYP3A4 inhibitors also inhibit P-gp (e.g., verapamil, ketoconazole), reducing efflux at the blood-brain barrier and
increasing brain penetration. Option B is opposite. Option C: P-gp induction is not typical with CYP3A4 inhibitors.
Option D: P-gp and CYP3A4 often work synergistically; inhibition of one does not fully compensate.
9 A drug is eliminated solely by glomerular filtration (no secretion or reabsorption). The patient has a glomerular
filtration rate (GFR) of 30 mL/min. If the normal GFR is 120 mL/min and the drug's normal half-life is 4 hours,
what is the expected half-life in this patient?
A) 1 hour
B) 4 hours
C) 12 hours
D) 16 hours
Answer: D
Rationale: For a drug eliminated solely by filtration, clearance is proportional to GFR. Half-life is inversely
proportional to clearance: t½ 1/CL. If GFR is reduced to 30/120 = 1/4 of normal, clearance is 1/4, so half-life
increases 4-fold: 4 * 4 = 16 hours. Option A (1 hr) would be increased clearance. Option B (4 hr) assumes no
change. Option C (12 hr) is 3-fold, not 4-fold.
10 A drug has an elimination rate constant (k) of 0.2 hr¹ and a volume of distribution (Vd) of 50 L. If a continuous
IV infusion is started at a rate of 100 mg/hr, what is the predicted steady-state concentration (Css)?
A) 5 mg/L
B) 10 mg/L
C) 20 mg/L
D) 40 mg/L
Answer: B
Rationale: C l e a r a n c e ( C L ) = k * V d = 0 . 2 h r{ ¹ * 5 0
mg/L. Option A (5 mg/L) would require CL=20 L/hr. Option C (20 mg/L) would require CL=5 L/hr. Option D (40
mg/L) would require CL=2.5 L/hr.
